(Q46708226)

English

Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial

scientific article published on 13 March 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Essack Mitha

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

H Ralph Schumacher

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Leon Fouche

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Shue-Fen Luo

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Steven P Weinstein

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

George D Yancopoulos

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Jian Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Shirletta King-Davis

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Robert R Evans

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

publication date

13 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

52

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

1285-1292

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Mechanisms of inflammation in gout

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Crystal-induced arthropathies: recent investigative advances

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Gout Study Group: update on hyperuricemia and gout.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Evil humors take their toll as innate immunity makes gouty joints TREM-ble

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Serum urate levels and gout flares: analysis from managed care data

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Adherence with urate-lowering therapies for the treatment of gout

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Comparison of drug adherence rates among patients with seven different medical conditions.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Prevalence of contraindications and prescription of pharmacologic therapies for gout

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Gout-associated uric acid crystals activate the NALP3 inflammasome

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Case of anakinra as a steroid-sparing agent for gout inflammation

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Cytokine traps: multi-component, high-affinity blockers of cytokine action

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Preliminary criteria for the classification of the acute arthritis of primary gout

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

The risk of infections with biologic therapies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET114

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KET114

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23485476

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46708226&oldid=2127669810"